Literature DB >> 7758109

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity.

J A Symons1, A Alcamí, G L Smith.   

Abstract

Vaccinia virus (VV) and other orthopoxviruses express a soluble type I interferon (IFN) receptor that for VV strain Western Reserve is encoded by gene B18R. The 60-65 kDa glycoprotein is related to the interleukin-1 receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN receptors, which belong to the class II cytokine receptor family. The receptor has high affinity (KD, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to human, rabbit, bovine, rat, and mouse type I IFNs. This may have aided VV replication in multiple host species during evolution. A VV B18R deletion mutant is attenuated in a murine intranasal model. This type I IFN receptor represents the fourth VV protein that interferes with IFN and the fourth soluble cytokine receptor expressed by poxviruses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758109     DOI: 10.1016/0092-8674(95)90076-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  194 in total

1.  Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon.

Authors:  R Deonarain; A Alcamí; M Alexiou; M J Dallman; D R Gewert; A C Porter
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

3.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Poxvirus-induced immunostimulating effects on porcine leukocytes.

Authors:  V Fachinger; T Schlapp; W Strube; N Schmeer; A Saalmüller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication.

Authors:  Anderson A Andrade; Patrícia N G Silva; Anna C T C Pereira; Lirlândia P De Sousa; Paulo C P Ferreira; Ricardo T Gazzinelli; Erna G Kroon; Catherine Ropert; Cláudio A Bonjardim
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

6.  Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling.

Authors:  Mariana G Bego; Johanne Mercier; Eric A Cohen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

7.  Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway.

Authors:  Peihong Dai; Hua Cao; Taha Merghoub; Francesca Avogadri; Weiyi Wang; Tanvi Parikh; Chee-Mun Fang; Paula M Pitha; Katherine A Fitzgerald; Masmudur M Rahman; Grant McFadden; Xiaoyu Hu; Alan N Houghton; Stewart Shuman; Liang Deng
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 8.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

9.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Genetic basis for adverse events after smallpox vaccination.

Authors:  David M Reif; Brett A McKinney; Alison A Motsinger; Stephen J Chanock; Kathryn M Edwards; Michael T Rock; Jason H Moore; James E Crowe
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.